Talis Biomedical (NASDAQ:TLIS) Trading Down 4.8% – Here’s Why

Talis Biomedical Co. (NASDAQ:TLIS) traded down 4.8% on Friday . The stock traded as low as $1.60 and last traded at $1.60. 33,850 shares changed hands during mid-day trading, an increase of 854% from the average session volume of 3,548 shares. The stock had previously closed at $1.68.

Talis Biomedical Price Performance

The firm has a market capitalization of $2.92 million, a price-to-earnings ratio of -0.06 and a beta of 1.52. The business has a 50-day moving average of $1.71 and a two-hundred day moving average of $1.91.

Institutional Trading of Talis Biomedical

An institutional investor recently raised its position in Talis Biomedical stock. BML Capital Management LLC increased its position in Talis Biomedical Co. (NASDAQ:TLIS) by 481.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 248,702 shares of the company’s stock after purchasing an additional 205,959 shares during the quarter. Talis Biomedical makes up 0.3% of BML Capital Management LLC’s portfolio, making the stock its 24th largest holding. BML Capital Management LLC owned approximately 13.66% of Talis Biomedical worth $460,000 at the end of the most recent quarter. Institutional investors and hedge funds own 43.77% of the company’s stock.

Talis Biomedical Company Profile

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.